Commercial Perspectives: Drug Treatment in End-Stage Renal Disease - The Price of Failure

Introduction

Increased prevalence of diabetes, obesity, and cardiovascular disease, all causal factors of renal disease, drives growth of the end-stage renal disease (ESRD) sector. On average, an ESRD patient uses >$7,000 of drugs/year, representing a significant opportunity for pharmaceutical companies in treating the symptoms, comorbid conditions and treatment side effects of ESRD.

Scope

Analysis of the ESRD sector in the US, and in the 5 major European markets Germany, France, UK, Italy and Spain

Analysis of issues facing the ESRD market: rising prevalence, treatment costs and greater focus on prevention, and differences in treatment patterns

Insight into drugs in the treatment of comorbidities of ESRD including: hypertension, dyslipidemia and diabetes

Review of drugs in the treatment of dialysis side effects including: erythropoietins, IV iron, vitamin D and phosphate lowering drugs

Highlights

The ESRD market is growing at a rate of 6% in the US, 7% in Japan and 4% in Europe. It is a large cost burden on healthcare payors with treatment costs increasing by a CAGR of 5% to over $60,000 per patient per year.

Diabetes and hypertension are considered a causal factor in >72% of the cases of ESRD and cardiovascular disease is the cause of death for over 60% of ESRD patients. The ESRD market represents around 1% of the cardiovascular market, but the overall chronic kidney disease (CKD) market is a much larger target population.

Costs of drugs directly treating symptoms of ESRD represent over 14% of the treatment costs. Erythropoietin treatment of renal-disease-related anemia represents over 70% of these costs, followed by vitamin D treatment of secondary hyperparathyroidism. Costs are expected to reduce with the introduction of biosimilars or biogenerics in 2007 to 2010.

Reasons to Purchase

Gain insight into the dynamics and key issues in the ESRD market

Understand how to position drugs used to treat the comorbidities of ESRD patients

Look at the opportunities in treating dialysis patients

January 2006

Pages: 118

Format: PDF
Table of Contents
Price: $7,600.00 / GBP3,800.00